与其它抗精神病药相比,氯氮平所致粒细胞缺乏症风险的长期持续性:芬兰全国性队列与病例对照研究
该研究基于芬兰全国人群,纳入1972至2014年间诊断精神分裂症或分裂情感性障碍者,比较氯氮平与非氯氮平治疗期间粒细胞缺乏症的长期风险。结果显示氯氮平所致粒细胞缺乏症风险随时间陡降,但可能持续高于非氯氮平抗精神病药;绝对风险超额较小。
要点
- 氯氮平治疗者粒细胞缺乏症累积发生率为1.37%(95%CI 0.58-3.16),非氯氮平治疗者为0.13%(0.04-0.23)。
- 使用氯氮平不足6个月者粒细胞缺乏症调整比值比为36.01(95%CI 16.79-77.22),使用54个月及以上者降至4.38(1.86-10.34)。
- 3559名起始氯氮平治疗者中仅1人死于氯氮平所致粒细胞缺乏症。
核心结论
- 氯氮平所致粒细胞缺乏症风险随时间陡降,但可能持续高于非氯氮平抗精神病药。
- 作者认为长期风险超额绝对值较小,放宽长期中性粒细胞监测或可有利于发挥氯氮平长期使用的优势。
研究设计与样本
- 基于芬兰全国人群的队列研究,纳入1972至2014年间诊断精神分裂症或分裂情感性障碍者,观察期1996至2017年共22年。
- 采用Kaplan-Meier模型分析氯氮平与非氯氮平治疗期间粒细胞缺乏症的诊断时间。
- 嵌套病例对照模型按性别、年龄、诊断后时间及是否在发病队列中匹配,比例1:5,共纳入病例398例、对照1987例。
- 比较多组氯氮平与非氯氮平抗精神病药使用时长与模态使用时长,采用多变量回归模型得出调整比值比(aOR)。
主要发现
- 共识别61769例精神分裂症或分裂情感性障碍患者,其中氯氮平治疗14037例、非氯氮平抗精神病药治疗47732例;平均年龄46.67岁(IQR 34.44-57.61),女性30721例(49.7%)、男性31048例(50.3%)。
- 398例诊断为粒细胞缺乏症,其中氯氮平治疗231例、非氯氮平抗精神病药治疗167例。
- 氯氮平治疗者粒细胞缺乏症累积发生率为1.37%(95%CI 0.58-3.16),非氯氮平抗精神病药治疗者为0.13%(0.04-0.23)。
- 病例对照模型中,氯氮平所致粒细胞缺乏症风险随时间陡降:使用不足6个月aOR为36.01(95%CI 16.79-77.22),使用54个月及以上aOR为4.38(1.86-10.34)。
- 3559名起始氯氮平治疗者中仅1人死于氯氮平所致粒细胞缺乏症。
关键数值与推荐
- 氯氮平治疗者粒细胞缺乏症累积发生率为1.37%(95%CI 0.58-3.16),非氯氮平抗精神病药治疗者为0.13%(0.04-0.23)。
- 使用氯氮平不足6个月者粒细胞缺乏症aOR为36.01(95%CI 16.79-77.22),使用54个月及以上者为4.38(1.86-10.34)。
- 3559名起始氯氮平治疗者中仅1人死于氯氮平所致粒细胞缺乏症。
临床怎么用
- 作者认为,鉴于氯氮平广泛使用不足,放宽长期中性粒细胞监测或可有利于发挥氯氮平长期使用的优势,包括更高预期寿命,而不 incurring 不可耐受的氯氮平所致粒细胞缺乏症风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Agranulocytosis is a life-threatening side-effect of clozapine, the only approved drug for treatment-resistant schizophrenia. The long-term profile of this complication has not yet been well established. Here we aim to describe the risk of clozapine-induced agranulocytosis over the long term. METHODS: We used the entire population of Finland to identify people diagnosed with schizophrenia or schizoaffective disorder between 1972 and 2014 and developed a Kaplan-Meier model of time to diagnosis of agranulocytosis during clozapine versus non-clozapine treatment over a 22-year observation period (1996 to 2017). Next, we developed a nested case-control model for agranulocytosis matching by sex, age, time since diagnosis, and being in the incident cohort on a 1 to 5 ratio. Various durations of use for clozapine and non-clozapine antipsychotic treatment were compared to the modal antipsychotic use duration, deriving adjusted odds ratios (aORs) in a multivariable regression model. Recurrence and lethality rates for clozapine-induced agranulocytosis were described. These data reflect on all individuals with lived experience of schizophrenia in Finland during the study time, although individuals with lived experience were not included in the design of the study. FINDINGS: We identified 61 769 people with schizophrenia or schizoaffective disorder (14 037 individuals treated with clozapine and 47 732 individuals treated with non-clozapine antipsychotics), with a mean age of 46·67 years (IQR 34·44-57·61), of whom 30 721 (49·7%) were female and 31 048 (50·3%) were male (data on ethnicity not available). Among those, 398 individuals were diagnosed with agranulocytosis (231 individuals treated with clozapine and 167 individuals treated with non-clozapine antipsychotics), representing a cumulative incidence of agranulocytosis for 1·37% (95% CI 0·58-3·16) on clozapine and 0·13% (0·04-0·23) on non-clozapine antipsychotics. In the case (n=398) versus control (n=1987) model, the risk of clozapine-induced agranulocytosis decreased steeply over time from an aOR of 36·01 (95% CI 16·79-77·22) for less than 6 months on clozapine to 4·38 (1·86-10·34) for clozapine use of 54 months or more. Only one of 3559 individuals starting clozapine died because of clozapine-induced agranulocytosis. INTERPRETATION: The risk of clozapine-induced agranulocytosis decreases steeply over time but might be persistently greater than that of non-clozapine antipsychotics. This long-term risk excess seems small in absolute terms compared with the known magnitude of the advantages of clozapine in relevant outcomes, including life expectancy. Given the widespread underuse of clozapine, relaxing the long-term neutrophil monitoring could favour the advantages of long-term clozapine use, including greater life expectancy, without incurring the intolerable risk of clozapine-induced agranulocytosis. FUNDING: Northwell Health and Sigrid Jusèlius Foundation.
引用
- Rubio JM, Kane JM, Tanskanen A, et al. Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland. Lancet Psychiatry. 2024. PMID: 38697177. doi:10.1016/S2215-0366(24)00097-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。